Overactive Bladder Treatment (OAB) Market worth $4.2 Billion by 2027 - Exclusive Report by MarketsandMarkets™
CHICAGO, July 5, 2022
CHICAGO, July 5, 2022 /PRNewswire/ -- According to the new market research report "Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027", published by MarketsandMarkets™, the global Overactive Bladder Treatment Market is projected to reach USD 4.2 Billion by 2027 from USD 3.5 Billion in 2022, at a CAGR of 3.6% during the forecast period.
Browse in-depth TOC on "Overactive Bladder Treatment (OAB) Market"
156 – Tables
48 – Figures
198 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219938791
The Increasing number of patients undergoing neuromodulation coupled with launch of novel drugs is likely to drive the growth of market. Rising number of patient with overactive bladder coupled with increasing awareness among the developing countries is anticipated to increase demand for treatment options in coming years, this factor is expected to upsurge the growth during the forecast period.
The others segment is estimated to grow with highest CAGR during the forecast period of overactive bladder treatment market
Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Other treatment segment is expected to grow at faster pace owing to launch of several novel drugs in the pipeline. For instance, Urovant Sciences' URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms currently under Phase 2 clinical trials.
The Idiopathic OAB is registered to grow at faster pace during the forecast period of 2022-2027.
Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder & neurogenic overactive bladder. Rising aging population is one of the factor increasing number of patients suffering from idiopathic overactive bladder hence projecting the growth of the market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=219938791
North America has registered fastest growth rate during the forecast period in overactive bladder treatment market
The global overactive bladder treatments market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is anticipated to grow at faster pace owing to favorable reimbursement policies and increased demand for treatment in the region.
The overactive bladder treatment market is fragmented in nature with prominent players operating in this market such as are Astellas Pharma (Japan), Teva Pharmaceutical Industries (Israel), Pfizer (US), Medtronic (Ireland), AbbVie (US), Viatris (US), Hisamitsu Pharmaceutical (Japan), Johnson & Johnson Services (US), Endo Pharmaceuticals Lupin (India) , Amneal Pharmaceuticals (US), Sun Pharmaceutical Industries (India) and among others.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=219938791
Browse Adjacent Markets: Pharmaceuticals Market Research Reports & Consulting
Browse Related Reports:
Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025
Urology Devices Market by Product ((Dialysis, Endoscopes, Lasers, Lithotripsy, Robotic System), (Guidewires, Catheters, Stents)), Application (Kidney Diseases, Urological Cancer, BPH), End User (Hospital, Dialysis Center, Homecare) - Global Forecast to 2026
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/overactive-bladder-treatment-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/overactive-bladder-treatment.asp